These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Endogenous glucocorticoids attenuate Shiga toxin-2-induced toxicity in a mouse model of haemolytic uraemic syndrome. Gómez SA; Fernández GC; Vanzulli S; Dran G; Rubel C; Berki T; Isturiz MA; Palermo MS Clin Exp Immunol; 2003 Feb; 131(2):217-24. PubMed ID: 12562380 [TBL] [Abstract][Full Text] [Related]
7. Development of a Mouse Model of Shiga Toxin 2 (Stx2) Intoxication for Testing Therapeutic Agents Against Hemolytic Uremic Syndrome (HUS). Mejias MP; Fernandez-Brando RJ; Ramos MV; Abrey-Recalde MJ; Zotta E; Meiss R; Palermo MS Curr Pharm Des; 2016; 22(34):5294-5299. PubMed ID: 27356777 [TBL] [Abstract][Full Text] [Related]
8. Relevance of neutrophils in the murine model of haemolytic uraemic syndrome: mechanisms involved in Shiga toxin type 2-induced neutrophilia. Fernandez GC; Lopez MF; Gomez SA; Ramos MV; Bentancor LV; Fernandez-Brando RJ; Landoni VI; Dran GI; Meiss R; Isturiz MA; Palermo MS Clin Exp Immunol; 2006 Oct; 146(1):76-84. PubMed ID: 16968401 [TBL] [Abstract][Full Text] [Related]
9. Detection and characterization of circulating microvesicles containing Shiga toxin type 2 in a rat model of Hemolytic Uremic Syndrome. Sacerdoti F; Gomez FD; Jancic C; Lombardo T; Pascuale CA; Moretton MA; Chiappetta DA; Ibarra C; Amaral MM Toxicon; 2023 Dec; 236():107349. PubMed ID: 37979924 [TBL] [Abstract][Full Text] [Related]
10. The efficacy of recombinant human soluble thrombomodulin for the treatment of shiga toxin-associated hemolytic uremic syndrome model mice. Suyama K; Kawasaki Y; Miyazaki K; Kanno S; Ono A; Ohara S; Sato M; Hosoya M Nephrol Dial Transplant; 2015 Jun; 30(6):969-77. PubMed ID: 25694534 [TBL] [Abstract][Full Text] [Related]
11. Response to Shiga toxin 1 and 2 in a baboon model of hemolytic uremic syndrome. Siegler RL; Obrig TG; Pysher TJ; Tesh VL; Denkers ND; Taylor FB Pediatr Nephrol; 2003 Feb; 18(2):92-6. PubMed ID: 12579394 [TBL] [Abstract][Full Text] [Related]
12. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. Morigi M; Galbusera M; Gastoldi S; Locatelli M; Buelli S; Pezzotta A; Pagani C; Noris M; Gobbi M; Stravalaci M; Rottoli D; Tedesco F; Remuzzi G; Zoja C J Immunol; 2011 Jul; 187(1):172-80. PubMed ID: 21642543 [TBL] [Abstract][Full Text] [Related]
13. LPS-primed CD11b Niu S; Paluszynski J; Bian Z; Shi L; Kidder K; Liu Y Sci Rep; 2018 Mar; 8(1):3994. PubMed ID: 29507316 [TBL] [Abstract][Full Text] [Related]
14. Human monocytes stimulated by Shiga toxin 1a via globotriaosylceramide release proinflammatory molecules associated with hemolytic uremic syndrome. Brigotti M; Carnicelli D; Arfilli V; Porcellini E; Galassi E; Valerii MC; Spisni E Int J Med Microbiol; 2018 Oct; 308(7):940-946. PubMed ID: 29983334 [TBL] [Abstract][Full Text] [Related]
15. Interleukin-33/ST2 signaling contributes to the severity of hemolytic uremic syndrome induced by enterohemorrhagic Escherichia coli. Yamada S; Shimizu M; Kuroda M; Inoue N; Sugimoto N; Yachie A Clin Exp Nephrol; 2019 Apr; 23(4):544-550. PubMed ID: 30467800 [TBL] [Abstract][Full Text] [Related]
16. A murine model of HUS: Shiga toxin with lipopolysaccharide mimics the renal damage and physiologic response of human disease. Keepers TR; Psotka MA; Gross LK; Obrig TG J Am Soc Nephrol; 2006 Dec; 17(12):3404-14. PubMed ID: 17082244 [TBL] [Abstract][Full Text] [Related]
17. Mouse model for hemolytic uremic syndrome induced by outer membrane vesicles of Escherichia coli O157:H7. Kim SH; Lee YH; Lee SH; Lee SR; Huh JW; Kim SU; Chang KT FEMS Immunol Med Microbiol; 2011 Dec; 63(3):427-34. PubMed ID: 22029600 [TBL] [Abstract][Full Text] [Related]
19. Protective role of nitric oxide in mice with Shiga toxin-induced hemolytic uremic syndrome. Dran GI; Fernández GC; Rubel CJ; Bermejo E; Gomez S; Meiss R; Isturiz MA; Palermo MS Kidney Int; 2002 Oct; 62(4):1338-48. PubMed ID: 12234304 [TBL] [Abstract][Full Text] [Related]
20. Lack of specific binding of Shiga-like toxin (verocytotoxin) and non-specific interaction of Shiga-like toxin 2 antibody with human polymorphonuclear leucocytes. Geelen JM; van der Velden TJ; Te Loo DM; Boerman OC; van den Heuvel LP; Monnens LA Nephrol Dial Transplant; 2007 Mar; 22(3):749-55. PubMed ID: 17127697 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]